Crossmark Global Holdings Inc. Takes $1.08 Million Position in Galapagos NV (NASDAQ:GLPG)

Crossmark Global Holdings Inc. bought a new stake in Galapagos NV (NASDAQ:GLPG) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 37,386 shares of the biotechnology company’s stock, valued at approximately $1,077,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Headlands Technologies LLC grew its stake in Galapagos by 949.3% in the first quarter. Headlands Technologies LLC now owns 787 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 712 shares during the period. GAMMA Investing LLC grew its position in Galapagos by 140.7% in the 3rd quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 736 shares during the period. Signaturefd LLC grew its position in Galapagos by 48.1% in the 2nd quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 1,258 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Galapagos by 63.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 1,510 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in Galapagos by 21.6% during the second quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock worth $113,000 after buying an additional 814 shares during the last quarter. 32.46% of the stock is owned by institutional investors and hedge funds.

Galapagos Stock Performance

Shares of NASDAQ GLPG opened at $27.90 on Friday. The stock’s 50 day moving average price is $28.92 and its 200-day moving average price is $27.62. Galapagos NV has a twelve month low of $24.16 and a twelve month high of $42.46.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Leerink Partners began coverage on shares of Galapagos in a research report on Monday, September 9th. They set a “market perform” rating and a $24.00 target price for the company. Raymond James lowered Galapagos from an “outperform” rating to a “market perform” rating in a report on Friday, August 2nd. Royal Bank of Canada dropped their target price on Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a report on Friday, November 1st. Finally, Leerink Partnrs upgraded Galapagos to a “hold” rating in a report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $30.75.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.